Cabazitaxel Accord (cabazitaxel)
Generic
- Region
- 🇪🇺 EU
- Active substance
- cabazitaxel
- Company
- Accord Healthcare S.L.U.
- Status
- Authorised
- Therapeutic area
- Prostatic Neoplasms, Castration-Resistant
- CHMP opinion
- Thu 30 Apr 2020
- EU approval
- Fri 28 Aug 2020
- Designations
- Generic
- Application
- EMEA/H/C/005178
- ATC
- L01CD04
- Official record
- www.ema.europa.eu
Indication
Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Jevtana Authorised · Sanofi Winthrop Industrie
- 🇪🇺 Cabazitaxel Teva Refused · Teva B.V.
Follow Cabazitaxel Accord
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.